Evidence map›Paper›PMID 30719309›Full record

ArticleSAGE open medical case reports2019

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.

Ahmad Haider, Karim Haider, Farid Saad, Markolf Hanefeld

Open access · goldAbstract readCase Reports
In one paragraph

Article in SAGE open medical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ahmad HaiderPrivate Urology Practice, Bremerhaven, Germany.
Karim HaiderPrivate Urology Practice, Bremerhaven, Germany.
Farid SaadGlobal Medical Affairs Andrology, Bayer AG, Berlin, Germany.ORCID https://orcid.org/0000-0002-0449-6635
Markolf HanefeldStudienzentrum Metabolisch-Vaskuläre Medizin, GWT-TUD GmbH, Dresden, Germany.
Gulf Medical University · AEGWT-TUD (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.

Indexed as

cardiometabolic risk factors“late-onset” hypogonadismobesityTestosterone therapytype 2 diabetes

Identifiers

PMID30719309
PMCPMC6349975
OpenAlexW2910540501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.